Bliss GVS Pharma Limited (BLISSGVS.BO)
INR 120.15
(3.0%)
INR 120.15
(3.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.23 Billion INR | 26.96% |
| 2022 | 978.6 Million INR | 2.99% |
| 2021 | 950.22 Million INR | 14.45% |
| 2020 | 830.24 Million INR | -21.48% |
| 2019 | 1.05 Billion INR | -25.29% |
| 2018 | 1.41 Billion INR | 74.23% |
| 2017 | 812.35 Million INR | 20.26% |
| 2016 | 675.47 Million INR | -49.0% |
| 2015 | 1.32 Billion INR | 11.24% |
| 2014 | 1.19 Billion INR | 36.24% |
| 2013 | 873.94 Million INR | -16.26% |
| 2012 | 1.04 Billion INR | 56.26% |
| 2011 | 667.84 Million INR | 297.1% |
| 2010 | -338.83 Million INR | -170.89% |
| 2009 | 477.99 Million INR | 12.43% |
| 2008 | 425.15 Million INR | 16.11% |
| 2007 | 366.15 Million INR | 460.72% |
| 2006 | 65.3 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 274.81 Million INR | 27.82% |
| 2024 Q2 | 344.95 Million INR | 25.52% |
| 2023 Q2 | 479.77 Million INR | 166.17% |
| 2023 Q1 | 180.24 Million INR | 1229.16% |
| 2023 Q4 | 215.01 Million INR | -41.48% |
| 2023 Q3 | 367.39 Million INR | -23.42% |
| 2023 FY | 1.24 Billion INR | 26.96% |
| 2022 Q2 | 199.44 Million INR | -41.85% |
| 2022 Q4 | 13.56 Million INR | -96.85% |
| 2022 Q3 | 430.47 Million INR | 115.83% |
| 2022 Q1 | 343.01 Million INR | 115.78% |
| 2022 FY | 978.6 Million INR | 2.99% |
| 2021 FY | 950.22 Million INR | 14.45% |
| 2021 Q2 | 251.11 Million INR | -17.03% |
| 2021 Q1 | 302.67 Million INR | 56.89% |
| 2021 Q4 | 158.96 Million INR | 136.24% |
| 2021 Q3 | -438.59 Million INR | -274.66% |
| 2020 Q3 | 380.31 Million INR | 70.18% |
| 2020 Q2 | 223.47 Million INR | 0.52% |
| 2020 Q4 | 192.92 Million INR | -49.27% |
| 2020 Q1 | 222.32 Million INR | -27.65% |
| 2020 FY | 830.24 Million INR | -21.48% |
| 2019 Q1 | 482.97 Million INR | 11.85% |
| 2019 Q2 | 348.65 Million INR | -27.81% |
| 2019 Q3 | 354.87 Million INR | 1.79% |
| 2019 Q4 | 307.27 Million INR | -13.41% |
| 2019 FY | 1.05 Billion INR | -25.29% |
| 2018 Q2 | 640.63 Million INR | 96.98% |
| 2018 Q1 | 325.23 Million INR | -14.86% |
| 2018 FY | 1.41 Billion INR | 74.23% |
| 2018 Q4 | 431.81 Million INR | 15.33% |
| 2018 Q3 | 374.43 Million INR | -41.55% |
| 2017 Q1 | 624.98 Million INR | -8.21% |
| 2017 FY | 812.35 Million INR | 20.26% |
| 2017 Q4 | 382.01 Million INR | -12.85% |
| 2017 Q3 | 438.37 Million INR | -24.1% |
| 2017 Q2 | 577.54 Million INR | -7.59% |
| 2016 Q4 | 680.87 Million INR | 63.58% |
| 2016 Q3 | 416.24 Million INR | 2.43% |
| 2016 Q2 | 406.36 Million INR | -9.18% |
| 2016 Q1 | 447.44 Million INR | -11.33% |
| 2016 FY | 675.47 Million INR | -49.0% |
| 2015 Q3 | 325.87 Million INR | -28.21% |
| 2015 Q1 | 383.7 Million INR | 0.0% |
| 2015 Q4 | 504.6 Million INR | 54.84% |
| 2015 FY | 1.32 Billion INR | 11.24% |
| 2015 Q2 | 453.91 Million INR | 18.3% |
| 2014 FY | 1.19 Billion INR | 36.24% |
| 2013 FY | 873.94 Million INR | -16.26% |
| 2012 Q2 | 366.34 Million INR | 48.07% |
| 2012 Q4 | 175.69 Million INR | -33.46% |
| 2012 FY | 1.04 Billion INR | 56.26% |
| 2012 Q1 | 247.4 Million INR | 0.0% |
| 2012 Q3 | 264.03 Million INR | -27.93% |
| 2011 FY | 667.84 Million INR | 297.1% |
| 2010 FY | -338.83 Million INR | -170.89% |
| 2009 FY | 477.99 Million INR | 12.43% |
| 2008 FY | 425.15 Million INR | 16.11% |
| 2007 FY | 366.15 Million INR | 460.72% |
| 2006 FY | 65.3 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 78.621% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 97.083% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 86.291% |
| Granules India Limited | 6.81 Billion INR | 81.941% |
| Indoco Remedies Limited | 1.29 Billion INR | 4.762% |
| Achyut Healthcare Limited | 4.43 Million INR | -27637.742% |
| Ajanta Pharma Limited | 19.67 Billion INR | 93.744% |
| Alkem Laboratories Limited | 19.46 Billion INR | 93.675% |
| Alpa Laboratories Limited | 184.49 Million INR | -567.22% |
| Brooks Laboratories Limited | 14.44 Million INR | -8424.938% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 28.326% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 98.182% |
| Eris Lifesciences Limited | 5.18 Billion INR | 76.243% |
| FDC Limited | 2.98 Billion INR | 58.777% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 81.068% |
| Gufic Biosciences Limited | 1.32 Billion INR | 7.437% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 72.153% |
| Ipca Laboratories Limited | 7.98 Billion INR | 84.575% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -142.261% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 910.098% |
| Lasa Supergenerics Limited | -458 Million INR | 368.775% |
| Laurus Labs Limited | 3.94 Billion INR | 68.824% |
| Lupin Limited | 28.04 Billion INR | 95.611% |
| Mankind Pharma Limited | 21.51 Billion INR | 94.279% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -1127.319% |
| Megasoft Limited | -121.1 Million INR | 1116.483% |
| NATCO Pharma Limited | 25.96 Billion INR | 95.258% |
| Piramal Pharma Limited | 4.55 Billion INR | 72.986% |
| RPG Life Sciences Limited | 2.29 Billion INR | 46.298% |
| Sigachi Industries Limited | 1.47 Billion INR | 16.48% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 98.82% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 73.283% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -393.88% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -116.073% |
| Windlas Biotech Limited | 1.29 Billion INR | 5.227% |
| ZIM Laboratories Limited | 253.82 Million INR | -384.973% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 97.144% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 129.915% |
| Divi's Laboratories Limited | 33.08 Billion INR | 96.279% |
| Hester Biosciences Limited | 364.81 Million INR | -237.436% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 55.815% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -169.045% |
| Bal Pharma Limited | 233.9 Million INR | -426.273% |
| Strides Pharma Science Limited | 5.22 Billion INR | 76.444% |
| Venus Remedies Limited | 534.65 Million INR | -130.244% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 60.647% |
| Nectar Lifesciences Limited | 923.8 Million INR | -33.253% |
| Shilpa Medicare Limited | 1.36 Billion INR | 9.901% |
| Aarti Drugs Limited | 7.14 Billion INR | 82.78% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 22.908% |
| Suven Life Sciences Limited | -1.22 Billion INR | 200.422% |
| Ind-Swift Limited | 1.22 Billion INR | -0.411% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 91.381% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 131.95% |
| Themis Medicare Limited | 392.58 Million INR | -213.56% |
| Hikal Limited | 32.11 Million INR | -3733.7% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 95.141% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -96.489% |
| Wockhardt Limited | -670 Million INR | 283.731% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 76.277% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -13474.173% |
| Neuland Laboratories Limited | 5.31 Billion INR | 76.853% |
| Morepen Laboratories Limited | 4.17 Billion INR | 70.507% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -491.685% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -4383.214% |